LILLY TRANSDERMAL XANOMELINE TO ENTER PHASE II FOR ALZHEIMER's AFTER ORAL FORMULATION DROPPED; NK-1 ANTAGONIST NEARING CLINICALS FOR CHRONIC PAIN
Lilly is testing a transdermal patch formulation of its Alzheimer's disease therapy xanomeline to see if the new formulation has a more favorable profile than oral xanomeline, Lilly Research Labs President August Watanabe, MD, told the Oppenheimer & Co. health care conference Nov. 10 in New York City.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth